Source:http://linkedlifedata.com/resource/pubmed/id/10592114
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2000-1-31
|
pubmed:abstractText |
The aim was to assess the frequency of von Hippel-Lindau disease (VHL) and the long-term prognosis of VHL and non-VHL patients among 110 consecutive patients with haemangioblastoma (HB) of the CNS treated between 1953 and 1993 at one neurosurgical unit. To reveal VHL manifestations we performed a detailed clinical and radiological examination (neuraxis and abdomen) (61/110), VHL-gene mutation analysis (40/110), and collection of all available clinical, imaging, operative and autopsy data from the hospitals involved. All patients were followed-up with a median of 14 years (excluding 14 operative deaths), and no patient was lost to follow-up. Altogether 49 patients died during the follow-up. In the 14 VHL patients (13%), HB(s) of the CNS were detected at a median age of 33 years, retinal HB(s) at 39 years, and renal cell carcinoma (RCC) at 43 years. The frequency of VHL in patients operated on for HB(s) was 29% before the age of 25 years, 19% between 25 and 45 years, and only 2% after 45 years. HB patients not meeting the VHL criteria had internal organ cysts in 14%. One non-VHL patient (4%) had two adjacent HBs in the same cyst wall. The growth rates of non-VHL and VHL-related HBs were similar as indicated by the median time to recurrence and the proliferation indices (MIB-1). Recurrence of the HB in patients whose primary operation was considered radical developed in four of the 10 VHL patients at a median of 19 years, and in nine of the 74 non-VHL patients at a median of 11 years. The median length of life of all VHL and non-VHL patients was 46 and 63 years, respectively. In VHL, RCC and HBs were equal causes of death.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0001-6268
|
pubmed:author |
pubmed-author:BöhlingTT,
pubmed-author:HaapasaloHH,
pubmed-author:JääskeläinenJJ,
pubmed-author:KääriäinenHH,
pubmed-author:KeroPP,
pubmed-author:LemetaSS,
pubmed-author:NiemeläMM,
pubmed-author:PoussaKK,
pubmed-author:PukkalaEE,
pubmed-author:SainioMM,
pubmed-author:SankilaRR,
pubmed-author:SummanenPP
|
pubmed:issnType |
Print
|
pubmed:volume |
141
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1147-56
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:10592114-Adolescent,
pubmed-meshheading:10592114-Adult,
pubmed-meshheading:10592114-Aged,
pubmed-meshheading:10592114-Central Nervous System Neoplasms,
pubmed-meshheading:10592114-Diagnostic Imaging,
pubmed-meshheading:10592114-Female,
pubmed-meshheading:10592114-Follow-Up Studies,
pubmed-meshheading:10592114-Hemangioblastoma,
pubmed-meshheading:10592114-Humans,
pubmed-meshheading:10592114-Male,
pubmed-meshheading:10592114-Middle Aged,
pubmed-meshheading:10592114-Neoplasm Recurrence, Local,
pubmed-meshheading:10592114-Reoperation,
pubmed-meshheading:10592114-Survival Rate,
pubmed-meshheading:10592114-von Hippel-Lindau Disease
|
pubmed:year |
1999
|
pubmed:articleTitle |
Long-term prognosis of haemangioblastoma of the CNS: impact of von Hippel-Lindau disease.
|
pubmed:affiliation |
Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland.
|
pubmed:publicationType |
Journal Article
|